Mayur Tanna

Mayur Tanna

Auto-generated profile, based on publicly available information

Mayur Tanna

Department of Biochemistry and Molecular Biology, The Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University of Jerusalem

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
AKAnees Khatib
Anees Khatib
BSBalakrishnan Solaimuthu
Balakrishnan Solaimuthu
MYMichal Ben Yosef
Michal Ben Yosef
ARAreej Abu Rmaileh
Areej Abu Rmaileh
MTMayur Tanna
Mayur Tanna
YSYoav D. Shaul
Yoav D. Shaul
One of the emerging hallmarks of cancer illustrates the importance of metabolic reprogramming, necessary to synthesize the building blocks required to fulfill the high demands of rapidly proliferating cells. However, the proliferation-independent instructive role of metabolic enzymes in tumor plasticity is still unclear. Here, we provide evidence that glutathione peroxidase 8 (GPX8), a poorly characterized enzyme that resides in the endoplasmic reticulum, is an essential regulator of tumor aggressiveness. We found that GPX8 expression was induced by the epithelial–mesenchymal transition (EMT) program. Moreover, in breast cancer patients, GPX8 expression significantly correlated with known mesenchymal markers and poor prognosis. Strikingly, GPX8 knockout in mesenchymal-like cells (MDA-MB-231) resulted in an epithelial-like morphology, down-regulation of EMT characteristics, and loss of cancer stemness features. In addition, GPX8 knockout significantly delayed tumor initiation and decreased its growth rate in mice. We found that these GPX8 loss-dependent phenotypes were accompanied by the repression of crucial autocrine factors, in particular, interleukin-6 (IL-6). In these cells, IL-6 bound to the soluble receptor (sIL6R), stimulating the JAK/STAT3 signaling pathway by IL-6 trans-signaling mechanisms, so promoting cancer aggressiveness. We observed that in GPX8 knockout cells, this signaling mechanism was impaired as sIL6R failed to activate the JAK/STAT3 signaling pathway. Altogether, we present the GPX8/IL-6/STAT3 axis as a metabolic-inflammatory pathway that acts as a robust regulator of cancer cell aggressiveness. Significance The cancer-dependent metabolic rewiring is mainly associated with the synthesis of building blocks that are needed to fulfill the proliferating cell metabolic requirements. However, the proliferation-independent instructive role of metabolic enzymes in tumor plasticity is still unclear. Here, we introduce glutathione peroxidase 8 (GPX8) as a metabolic enzyme that regulates cancer aggressiveness. We found that lack of GPX8 suppresses the aggressive phenotype and stemness features of the tumor cells. Mechanistically, these cells express a nonfunctional IL-6 receptor, which fails to interact with IL-6. This impaired binding hinders the activation of the downstream JAK/STAT3 signaling pathway, thereby inhibiting cancer cells transition to aggressive phenotypes. Thus, we present this GPX8/IL-6/STAT3 axis as a prototype of metabolic enzymes regulating cancer aggressiveness-associated signaling pathways.

16 May 2022 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
ARAreej Abu Rmaileh
Areej Abu Rmaileh
BSBalakrishnan Solaimuthu
Balakrishnan Solaimuthu
AKAnees Khatib
Anees Khatib
SLShirel Lavi
Shirel Lavi
MTMayur Tanna
Mayur Tanna
YSYoav D. Shaul
Yoav D. Shaul
The intricate neuronal wiring during development requires cytoskeletal reorganization orchestrated by signaling cues. Because cytoskeletal remodeling is a hallmark of cell migration, we investigated whether metastatic cancer cells exploit axon guidance proteins to migrate. Indeed, in breast cancer patients, we found a significant correlation between mesenchymal markers and the expression of dihydropyrimidinase-like 2 (DPYSL2), a regulator of cytoskeletal dynamics in growing axons. Strikingly, DPYSL2 knockout in mesenchymal-like breast cancer cells profoundly inhibited cell migration, invasion, stemness features, tumor growth rate, and metastasis. Next, we decoded the molecular mechanism underlying this phenomenon and revealed an interaction between DPYSL2 and Janus kinase 1 (JAK1). This binding is crucial for activating signal transducer and activator of transcription 3 (STAT3) and the subsequent expression of vimentin, the promigratory intermediate filament. These findings identify DPYSL2 as a molecular link between oncogenic signaling pathways and cytoskeletal reorganization in migrating breast cancer cells.

12 January 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
BSBalakrishnan Solaimuthu
Balakrishnan Solaimuthu
AKAnees Khatib
Anees Khatib
MTMayur Tanna
Mayur Tanna
AKAbdelrahman Karmi
Abdelrahman Karmi
新林新 林
新 林
YSYoav D. Shaul
Yoav D. Shaul
The epithelial–mesenchymal transition (EMT) program is crucial for transforming carcinoma cells into a partially mesenchymal state, enhancing their chemoresistance, migration, and metastasis. This shift in cell state is tightly regulated by cellular mechanisms that are not yet fully characterized. One intriguing EMT aspect is the rewiring of the proteoglycan landscape, particularly the induction of heparan sulfate proteoglycan (HSPG) biosynthesis. This proteoglycan functions as a co-receptor that accelerates cancer-associated signaling pathways through its negatively-charged residues. However, the precise mechanisms through which EMT governs HSPG biosynthesis and its role in cancer cell plasticity remain elusive. Here, we identified exostosin glycosyltransferase 1 (EXT1), a central enzyme in HSPG biosynthesis, to be selectively upregulated in aggressive tumor subtypes and cancer cell lines, and to function as a key player in breast cancer aggressiveness. Notably, ectopic expression of EXT1 in epithelial cells is sufficient to induce HSPG levels and the expression of known mesenchymal markers, subsequently enhancing EMT features, including cell migration, invasion, and tumor formation. Additionally, EXT1 loss in MDA-MB-231 cells inhibits their aggressiveness-associated traits such as migration, chemoresistance, tumor formation, and metastasis. Our findings reveal that EXT1, through its role in HSPG biosynthesis, governs signal transducer and activator of transcription 3 (STAT3) signaling, a known regulator of cancer cell aggressiveness. Collectively, we present the EXT1/HSPG/STAT3 axis as a central regulator of cancer cell plasticity that directly links proteoglycan synthesis to oncogenic signaling pathways.

17 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBalakrishnan Solaimuthu
Balakrishnan Solaimuthu
MLMichal Lichtenstein
Michal Lichtenstein
新林新 林
新 林
AKAnees Khatib
Anees Khatib
IPInbar Plaschkes
Inbar Plaschkes
YSYoav D. Shaul
Yoav D. Shaul
Several tumor suppressor genes do not follow the canonical function of cell cycle repressors. For example, fumarate hydratase (FH) is an evolutionary conserved TCA cycle enzyme that reversibly catalyzes the hydration of fumarate to L-malate and has a moonlight function in the DNA damage response (DDR). Interestingly, despite this enzyme’s essential role in central carbon metabolism, FH is inactive or absent in several tumors, such as hereditary leiomyomatosis and renal cell cancer (HLRCC). Accordingly, FH has a contradictory cellular function, as it is pro-survival through its role in the TCA cycle, yet its loss can drive tumorigenesis. These observations have supported the role of FH as a tumor suppressor. Here, we solved this contradiction by determining the molecular mechanisms that allow the cells to survive and even proliferate upon FH loss. We found that the cells’ response to FH loss is separated into two distinct time frames based on cell proliferation and DNA damage repair. During the early stages of FH loss, the cells’ proliferation and DNA damage repair are inhibited. However, over time the cells overcome the FH loss and form knockout clones, indistinguishable from WT cells in their proliferation rate. Due to the FH loss effect on DNA damage repair, we assumed that the recovered cells bear adaptive mutations. Therefore, we applied whole-exome sequencing to identify such mutated genes systematically. Indeed, we identified recurring mutations in genes belonging to the central oncogenic signaling pathways, such as JAK/STAT, which we validated to be impaired in FH-KO clones. Intriguingly, we demonstrated that these adaptive mutations are responsible for FH-KO cell proliferation under TCA cycle malfunction.

5 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
BSBalakrishnan Solaimuthu
Balakrishnan Solaimuthu
AKAnees Khatib
Anees Khatib
新林新 林
新 林
MTMayur Tanna
Mayur Tanna
MLMichal Lichtenstein
Michal Lichtenstein
YSYoav D. Shaul
Yoav D. Shaul
Carcinomas often exhibit aggressive characteristics, such as enhanced migration abilities, through the execution of the epithelial-mesenchymal transition (EMT) program. Heparan sulfate (HS) is a polysaccharide expressed on the surface of aggressive cancer cells, which acts as a co-receptor to stimulate EMT-associated signaling pathways. However, despite HS’ role in cancer aggressiveness, the mechanisms governing its EMT-dependent biosynthesis remains poorly understood. Here, we characterized the HS chain elongation enzyme, exostosin glycosyltransferase 1 (EXT1), as an essential component of the EMT program. We identified an EMT-dependent expression of EXT1 and its selective upregulation in aggressive tumor subtypes and cell lines. Overexpression of EXT1 in epithelial cells is sufficient to induce HS biosynthesis, cell migration, and invasion, form tumors in mice, and activate the STAT3 pathway. Moreover, its knockout in aggressive cells significantly inhibited their EMT-associated characteristics. These findings demonstrate a cellular mechanism by which metabolic processes regulate signaling pathways to govern cell state.